The July 2026 PBS update brings a number of important changes for oncology clinicians, with several new and expanded cancer medicine listings set to improve access to cancer treatments across breast, lung, blood and biliary tract cancers.
In this episode, Rachael Babin and Professor Craig Underhill discuss the clinical significance of the latest Pharmaceutical Benefits Scheme changes, including who is now eligible for treatment, what these listings mean for multidisciplinary care and why comprehensive biomarker testing continues to grow in importance.
In this episode:
PBS listing for pertuzumab (Perjeta®) in high-risk HER2-positive early breast cancer
Listing of alectinib (Alecensa®) for ALK-positive non-small cell lung cancer
Osimertinib (Tagrisso®) listing for EGFR-mutated unresectable Stage III NSCLC following chemoradiation
First PBS listing of romidepsin (Romidepsin-Reach®) for relapsed peripheral T-cell lymphoma
First PBS listing of futibatinib (Lytgobi®) for FGFR2-altered advanced cholangiocarcinoma
What the new broad (multi-cancer) PBS listing principles for PD-(L)1 inhibitors could mean for future cancer drug funding
Follow The PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Oncology Network. Innehållet i podden är skapat av The Oncology Network och inte av,
eller tillsammans med, Poddtoppen.
